Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced its participation in three upcoming industry and investor events in October 2024. These events include:
1. Pharma Partnering U.S. Summit (October 16-17) in Boston, MA, where Tariq Imam, VP of Business Development and Operations, will conduct one-on-one meetings.
2. BioFuture (October 28-30) in New York, NY, featuring a presentation by David J. Mazzo, PhD, President and CEO, on October 28 at 11:00 a.m. ET.
3. 17th Annual LD Micro Main Event (October 28-30) in Los Angeles, CA, where David J. Mazzo will present on October 29 at 11:00 a.m. PT.
These events offer opportunities for investors and industry professionals to learn more about Lisata's innovative therapies for advanced solid tumors and other serious diseases.
Lisata Therapeutics, Inc. (Nasdaq: LSTA), un'azienda farmaceutica in fase clinica, ha annunciato la sua partecipazione a tre eventi del settore e per investitori che si svolgeranno nell'ottobre 2024. Questi eventi includono:
1. Pharma Partnering U.S. Summit (16-17 ottobre) a Boston, MA, dove Tariq Imam, VP dello Sviluppo Aziendale e Operazioni, terrà incontri individuali.
2. BioFuture (28-30 ottobre) a New York, NY, che presenterà una conferenza di David J. Mazzo, PhD, Presidente e CEO, il 28 ottobre alle 11:00 ET.
3. 17th Annual LD Micro Main Event (28-30 ottobre) a Los Angeles, CA, dove David J. Mazzo presenterà il 29 ottobre alle 11:00 PT.
Questi eventi offrono opportunità per investitori e professionisti del settore di conoscere meglio le innovative terapie di Lisata per tumori solidi avanzati e altre malattie gravi.
Lisata Therapeutics, Inc. (Nasdaq: LSTA), una empresa farmacéutica en etapa clínica, ha anunciado su participación en tres eventos de la industria e inversionistas que se llevarán a cabo en octubre de 2024. Estos eventos incluyen:
1. Pharma Partnering U.S. Summit (16-17 de octubre) en Boston, MA, donde Tariq Imam, VP de Desarrollo de Negocios y Operaciones, conducirá reuniones individuales.
2. BioFuture (28-30 de octubre) en Nueva York, NY, que contará con una presentación de David J. Mazzo, PhD, Presidente y CEO, el 28 de octubre a las 11:00 a.m. ET.
3. 17th Annual LD Micro Main Event (28-30 de octubre) en Los Ángeles, CA, donde David J. Mazzo presentará el 29 de octubre a las 11:00 a.m. PT.
Estos eventos ofrecen oportunidades para que los inversionistas y profesionales de la industria conozcan más sobre las terapias innovadoras de Lisata para tumores sólidos avanzados y otras enfermedades graves.
리사타 제약 주식회사 (Nasdaq: LSTA)는 임상 단계의 제약 회사로, 2024년 10월에 개최되는 세 가지 산업 및 투자자 이벤트에 참여할 것이라고 발표했습니다. 이러한 이벤트는 다음과 같습니다:
1. Pharma Partnering U.S. Summit (10월 16-17일) 보스턴, MA에서 Tariq Imam 비즈니스 개발 및 운영 부사장이 일대일 회의를 진행합니다.
2. BioFuture (10월 28-30일) 뉴욕, NY에서 10월 28일 오전 11:00 ET에 David J. Mazzo 박사, 사장 겸 CEO의 발표가 예정되어 있습니다.
3. 17th Annual LD Micro Main Event (10월 28-30일) 로스앤젤레스, CA에서 David J. Mazzo가 10월 29일 오전 11:00 PT에 발표합니다.
이 행사들은 투자자와 업계 전문가들이 리사타의 혁신적인 고형 종양 및 기타 심각한 질병 치료법에 대해 더 많이 알 수 있는 기회를 제공합니다.
Lisata Therapeutics, Inc. (Nasdaq: LSTA), une entreprise pharmaceutique en phase clinique, a annoncé sa participation à trois événements à venir pour l'industrie et les investisseurs en octobre 2024. Ces événements incluent :
1. Pharma Partnering U.S. Summit (16-17 octobre) à Boston, MA, où Tariq Imam, VP du développement commercial et des opérations, conduira des réunions individuelles.
2. BioFuture (28-30 octobre) à New York, NY, avec une présentation de David J. Mazzo, PhD, Président et CEO, le 28 octobre à 11h00 ET.
3. 17th Annual LD Micro Main Event (28-30 octobre) à Los Angeles, CA, où David J. Mazzo fera une présentation le 29 octobre à 11h00 PT.
Ces événements offrent des opportunités aux investisseurs et aux professionnels du secteur d'en savoir plus sur les thérapies innovantes de Lisata pour les tumeurs solides avancées et d'autres maladies graves.
Lisata Therapeutics, Inc. (Nasdaq: LSTA), ein Unternehmen in der klinischen Phase, hat seine Teilnahme an drei bevorstehenden Branchen- und Investorenveranstaltungen im Oktober 2024 angekündigt. Diese Veranstaltungen umfassen:
1. Pharma Partnering U.S. Summit (16.-17. Oktober) in Boston, MA, bei dem Tariq Imam, VP für Geschäftsentwicklung und Betrieb, Einzelgespräche führen wird.
2. BioFuture (28.-30. Oktober) in New York, NY, mit einer Präsentation von David J. Mazzo, PhD, Präsident und CEO, am 28. Oktober um 11:00 Uhr ET.
3. 17th Annual LD Micro Main Event (28.-30. Oktober) in Los Angeles, CA, wo David J. Mazzo am 29. Oktober um 11:00 Uhr PT präsentieren wird.
Diese Veranstaltungen bieten Investoren und Branchenexperten die Möglichkeit, mehr über Lisatas innovative Therapien für fortgeschrittene solide Tumoren und andere ernste Erkrankungen zu erfahren.
- None.
- None.
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in October:
Pharma Partnering U.S. Summit (October 16-17, 2024)
Format: In-person (one-on-one meetings only)
Location: Hilton Boston Woburn, Boston, MA
Lisata representative: Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata
Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on the Pharma Partnering U.S. Summit and how to register, please click here or contact missy@pharma-partnering-summit.co.uk.
BioFuture (October 28-30, 2024; Virtual: November 5-7, 2024)
Format: In-person/Virtual
Location: Cure by Deerfield, New York, NY
Presentation Date: Monday, October 28, 2024
Presentation Time: 11:00 a.m. Eastern Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata
For more information on BioFuture and how to register, please click here or contact info@demy-colton.com.
17th Annual LD Micro Main Event (October 28-30, 2024)
Format: In-person/Virtual
Location: Luxe Sunset Blvd Hotel, Los Angeles, CA
Presentation Date: Tuesday, October 29, 2024
Presentation Time: 11:00 a.m. Pacific Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
Register to watch the virtual presentation: https://me24.sequireevents.com
For more information on the LD Micro Main Event and how to register, please click here or contact registration@ldmicro.com.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
FAQ
What events will Lisata Therapeutics (LSTA) participate in during October 2024?
Who will represent Lisata Therapeutics (LSTA) at the Pharma Partnering U.S. Summit in October 2024?
When and where will David J. Mazzo, PhD, present for Lisata Therapeutics (LSTA) at BioFuture in October 2024?
What is the date and time of Lisata Therapeutics' (LSTA) presentation at the 17th Annual LD Micro Main Event in October 2024?
